Cargando…

Review: Mechanotransduction in ovarian cancer: Shearing into the unknown

Ovarian cancer remains a deadly diagnosis with an 85% recurrence rate and a 5-year survival rate of only 46%. The poor outlook of this disease has improved little over the past 50 years owing to the lack of early detection, chemoresistance and the complex tumor microenvironment. Within the peritonea...

Descripción completa

Detalles Bibliográficos
Autores principales: Novak, Caymen, Horst, Eric, Mehta, Geeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AIP Publishing LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481715/
https://www.ncbi.nlm.nih.gov/pubmed/31069311
http://dx.doi.org/10.1063/1.5024386
_version_ 1783413780233846784
author Novak, Caymen
Horst, Eric
Mehta, Geeta
author_facet Novak, Caymen
Horst, Eric
Mehta, Geeta
author_sort Novak, Caymen
collection PubMed
description Ovarian cancer remains a deadly diagnosis with an 85% recurrence rate and a 5-year survival rate of only 46%. The poor outlook of this disease has improved little over the past 50 years owing to the lack of early detection, chemoresistance and the complex tumor microenvironment. Within the peritoneal cavity, the presence of ascites stimulates ovarian tumors with shear stresses. The stiff environment found within the tumor extracellular matrix and the peritoneal membrane are also implicated in the metastatic potential and epithelial to mesenchymal transition (EMT) of ovarian cancer. Though these mechanical cues remain highly relevant to the understanding and treatment of ovarian cancers, our current knowledge of their biological processes and their clinical relevance is deeply lacking. Seminal studies on ovarian cancer mechanotransduction have demonstrated close ties between mechanotransduction and ovarian cancer chemoresistance, EMT, enhanced cancer stem cell populations, and metastasis. This review summarizes our current understanding of ovarian cancer mechanotransduction and the gaps in knowledge that exist. Future investigations on ovarian cancer mechanotransduction will greatly improve clinical outcomes via systematic studies that determine shear stress magnitude and its influence on ovarian cancer progression, metastasis, and treatment.
format Online
Article
Text
id pubmed-6481715
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AIP Publishing LLC
record_format MEDLINE/PubMed
spelling pubmed-64817152019-05-08 Review: Mechanotransduction in ovarian cancer: Shearing into the unknown Novak, Caymen Horst, Eric Mehta, Geeta APL Bioeng Special Topic: Bioengineering of Cancer Ovarian cancer remains a deadly diagnosis with an 85% recurrence rate and a 5-year survival rate of only 46%. The poor outlook of this disease has improved little over the past 50 years owing to the lack of early detection, chemoresistance and the complex tumor microenvironment. Within the peritoneal cavity, the presence of ascites stimulates ovarian tumors with shear stresses. The stiff environment found within the tumor extracellular matrix and the peritoneal membrane are also implicated in the metastatic potential and epithelial to mesenchymal transition (EMT) of ovarian cancer. Though these mechanical cues remain highly relevant to the understanding and treatment of ovarian cancers, our current knowledge of their biological processes and their clinical relevance is deeply lacking. Seminal studies on ovarian cancer mechanotransduction have demonstrated close ties between mechanotransduction and ovarian cancer chemoresistance, EMT, enhanced cancer stem cell populations, and metastasis. This review summarizes our current understanding of ovarian cancer mechanotransduction and the gaps in knowledge that exist. Future investigations on ovarian cancer mechanotransduction will greatly improve clinical outcomes via systematic studies that determine shear stress magnitude and its influence on ovarian cancer progression, metastasis, and treatment. AIP Publishing LLC 2018-06-07 /pmc/articles/PMC6481715/ /pubmed/31069311 http://dx.doi.org/10.1063/1.5024386 Text en © 2018 Author(s). 2473-2877/2018/2(3)/000000/17 All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Special Topic: Bioengineering of Cancer
Novak, Caymen
Horst, Eric
Mehta, Geeta
Review: Mechanotransduction in ovarian cancer: Shearing into the unknown
title Review: Mechanotransduction in ovarian cancer: Shearing into the unknown
title_full Review: Mechanotransduction in ovarian cancer: Shearing into the unknown
title_fullStr Review: Mechanotransduction in ovarian cancer: Shearing into the unknown
title_full_unstemmed Review: Mechanotransduction in ovarian cancer: Shearing into the unknown
title_short Review: Mechanotransduction in ovarian cancer: Shearing into the unknown
title_sort review: mechanotransduction in ovarian cancer: shearing into the unknown
topic Special Topic: Bioengineering of Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481715/
https://www.ncbi.nlm.nih.gov/pubmed/31069311
http://dx.doi.org/10.1063/1.5024386
work_keys_str_mv AT novakcaymen reviewmechanotransductioninovariancancershearingintotheunknown
AT horsteric reviewmechanotransductioninovariancancershearingintotheunknown
AT mehtageeta reviewmechanotransductioninovariancancershearingintotheunknown